Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor or B-cell lymphoma and meets at least 1 of the following criteria:~  * Disease progression despite standard therapies~ * No standard therapies are available or such therapies are not anticipated to result in a durable response~ * Standard therapies are considered unsuitable or have been refused~* Able to take oral medications~* Life expectancy \> 12 weeks~* For the expansion cohort of the study, all subjects must be confirmed to be positive for ALK gene abnormalities~* Subjects with stable brain metastasis will be allowed~Exclusion Criteria:~* Active central nervous system (CNS) metastases or leptomeningeal involvement as assessed through medical history review and physical examination (dose escalation subjects only)~* Known history of a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)~* Known hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection~* Cardiac arrhythmias \> Grade 1 using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.03~* Class 3 or 4 New York Heart Association congestive heart failure, acute coronary syndrome, myocardial infarction or cerebrovascular accident within 6 months prior to Cycle 1, Day 1~* Inadequate bone marrow, renal, and/or hepatic function~* Confirmed active peptic ulcer disease or history of gastrointestinal bleeding within the past 3 months~* Known history of long QT syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP3026 (Type: EXPERIMENTAL): Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)

Based on this trial design, predict the completion outcome and termination type (if applicable).